Improving Health: Establishing Incentives and Sharing Value
The Professional Society for Health Economics and Outcome Research (ISPOR) is on a mission to promote health economics and outcomes research excellence to improve decision-making for healthcare globally.
The increasing availability of real-world data allows for the rapid generation of evidence and value measurement. As we rethink how we deliver healthcare in the new normal, EVERSANA is committed to improving health outcomes by addressing value challenges with evidence-driven, real-world evidence.
We’re proud to present the following at ISPOR EU, taking place November 16-19 virtually:
- PCN42: Systematic Differences Between Embraca and Olympiad Phase III Physician’s Choice Chemotherapy (PCT) Arms: A Focus on the First-Line (1L) Treatment of Metastatic Breast Cancer (MBC) Subpopulations
- PCN30: Systematic Review of Treatments in Metastatic Castration-Resistant Prostate Cancer (mCRPC) With DNA Damage Repair Gene Mutation (DDRm)
- PCN160: Systematic Literature Review (SLR) of Economic and Healthcare Resource Utilization Evidence in the Treatment of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
- PRS61: Targeted literature review of economic models used in health technology agency assessments in severe asthma
- Systematic Literature Review (SLR) of Economic and Healthcare Resource Utilization Evidence in the Treatment of Relapsed or Refractory B-Cell Lymphoma (LBCL)
- Health Utilities for Patients With HR-Positive/HER2-Negative Early Breast Cancer: A Systemic Literature Review
- Risk of Recurrence Among Patients With HR-Positive, HER2-Negative, Early Breast Cancer Receiving Adjuvant Endocrine Therapy: A Systematic Review and Meta-Analysis
- A Treatment Cost Model to Estimate Total Annual Costs for management of Patients With Transthyretin Amyloid Polyneuropathy in Spain
- Health Impact of Tafamidis in Transthyretin Amyloid Cardiomyopathy Patients: An Analysis From the ATTR-ACT and the Open-Label Extension Studies
- Targeted Literature Review of Economic Models Used in Health Technology Agency Assessments in Severe Asthma
- The Burden of Skeletal-Related Events in four Latin American Countries: Argentina, Brazil, Colombia, and Mexico
- UK (NICE) Conditional Recommendations Are Increasing over Time
- Time from EMA Approval to Initial HTA Decision in the UK (NICE)
Explore our library of publications to learn more about our RWE/HEOR efforts.